Please login to the form below

Not currently logged in
Email:
Password:

KCL appoints Luigi Martini as first chair of pharmaceutical innovation

Rainbow Medical Engineering director to lead new discoveries and inventions at King’s College London

Prof Luigi Gino Martini - King's College LondonKing's College London has appointed Rainbow Medical Engineering director Professor Luigi Martini as its first Chair of Pharmaceutical Innovation.

The newly-created position will see Martini work in the college's Institute of Pharmaceutical Science to strengthen its ability to ensure new discoveries and inventions across King's Health Partners are transferred to clinical and pharmaceutical development.

King's Health Partners is one of the UK's five academic health sciences centres, organisations that provide health care to patients and undertake health-related research. It combines the King's College London university and three NHS Foundation Trusts of Guy's and St Thomas', King's College Hospital and South London and Maudsley.

Prior to his role at Rainbow Medical, Martini was senior director of preclinical and pharmaceutical development for Emerging Markets and Asia Pacific at GlaxoSmithKline.

He is also a Fellow of the Royal Pharmaceutical Society of Great Britain, with research interests including the design of dosage form concepts for delivering personalised medicines and the development of biopharmaceuticals.

On his appointment, Martini said: “I am honoured to be joining this first-class institution, particularly in a role - the first of its kind in the UK - that demonstrates King's visionary leadership and ambition.”

6th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics